|
|
|
"
About the Novartis Vaccines global meningococcal franchise
Menveo is based on the same proprietary technology Novartis Vaccines pioneered to produce Menjugate, a meningococcal serogroup C conjugate vaccine approved outside the US since 2000 for use in individuals from age 2 months through adulthood. A Phase II study in infants published in the January 9, 2008, issue of the Journal of the American Medical Association reported that Menveo is the first meningococcal vaccine candidate to elicit a robust immune response in infants[1]. It is caused by the bacterium Neisseria meningitidis (N. Specific data related to this study will be presented by Dr.”
About AEOL 10150
AEOL 10150 is a small molecule that catalytically consumes reactive oxygen and nitrogen species (free radicals).
mexican pharmacies online xanax overdose xanax norvasc xanax addiction forum xanax and prozac death zanax or xanax
Through industry-leading scientific expertise, the company is focused on extending critical meningococcal vaccines research. Serogroups B and C are predominant in Europe. While Asia has primarily seen serogroup A, recent outbreaks of serogroup C have been noted.] Centers for Disease Control and Prevention.htm [3. A number of treated animals continued to be monitored until the end of six months and analysis of those animals is currently underway. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005